SKIN vs. TNDM, FNA, BLFS, LQDA, SSII, PLSE, INMD, MDXG, KMTS, and SIBN
Should you be buying Beauty Health stock or one of its competitors? The main competitors of Beauty Health include Tandem Diabetes Care (TNDM), Paragon 28 (FNA), BioLife Solutions (BLFS), Liquidia Technologies (LQDA), SS Innovations International (SSII), Pulse Biosciences (PLSE), InMode (INMD), MiMedx Group (MDXG), Kestra Medical Technologies (KMTS), and SiBone (SIBN). These companies are all part of the "medical equipment" industry.
Beauty Health vs. Its Competitors
Beauty Health (NASDAQ:SKIN) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.
In the previous week, Beauty Health had 15 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 22 mentions for Beauty Health and 7 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.04 beat Beauty Health's score of 0.86 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.
Beauty Health has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.
93.3% of Beauty Health shares are held by institutional investors. 41.0% of Beauty Health shares are held by company insiders. Comparatively, 1.9% of Tandem Diabetes Care shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Beauty Health has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Beauty Health, indicating that it is currently the more affordable of the two stocks.
Beauty Health presently has a consensus target price of $1.42, indicating a potential downside of 17.64%. Tandem Diabetes Care has a consensus target price of $32.71, indicating a potential upside of 107.71%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than Beauty Health.
Beauty Health has a net margin of -11.94% compared to Tandem Diabetes Care's net margin of -18.71%. Tandem Diabetes Care's return on equity of -57.33% beat Beauty Health's return on equity.
Summary
Beauty Health and Tandem Diabetes Care tied by winning 8 of the 16 factors compared between the two stocks.
Get Beauty Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKIN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SKIN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beauty Health Competitors List
Related Companies and Tools
This page (NASDAQ:SKIN) was last updated on 7/17/2025 by MarketBeat.com Staff
